Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.72 USD | -0.98% | +5.88% | +0.42% |
May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.42% | 60.22M | C | ||
-40.96% | 8.27B | A- | ||
-0.34% | 3.35B | C | ||
+0.37% | 2.34B | D+ | ||
-19.81% | 2.02B | - | B- | |
-22.06% | 1.62B | C+ | ||
+31.60% | 1.16B | B- | ||
-7.21% | 713M | C+ | ||
+15.67% | 696M | C- | ||
-34.59% | 488M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited